Immunovia appoints Patrik Dahlen as new CEO

Dahlen has extensive experience in the Life Sciences field as CEO of several international diagnostic companies. „Patrik has a truly solid commercial background in the diagnostic sector and will add valuable expertise through his proven track record of driving and expanding sales into international markets.“, Carl Borrebaeck, Chairman of Immunovia says.

He replaces Mats Grahn, who led Immunovia from development to commercial state in the course of seven years. He has now been nominated as a board member of Immunovia.

The Lund based company is specialised in developing and commercializing blood tests based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics for the early detection of cancer and autoimmune diseases.